Stoke Therapeutics (STOK) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.08

Estimate

-$0.91

Surprise

-18.1%

Score today

4.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Stoke Therapeutics (STOK) reported a wider loss than forecast — adjusted EPS of -$1.08 against the -$0.91 estimate (a 18.1% shortfall).

• Stoke Therapeutics Q3 2026 Earnings Call Transcript — benzinga, 2026-10-29
• Stoke Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-10-29
• Stoke Therapeutics Q3 EPS $(1.08) Misses $(0.93) Estimate, Sales $11.255M Beat $8.185M Estimate — benzinga, 2026-10-29

TrendMatrix currently rates STOK Sell at 4.2/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -18.1% surprise compares with a -16.5% four-quarter average. Next scheduled report: 2027-03-15.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$26.29

Price target

$40.35

Stop

$24.45

Upside to target

+53.5%

Reward-to-risk

3.6:1

Model outputs from TrendMatrix’s engine as of 2026-10-31 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.70B

P/E (fwd)

-7.2

52-week range

$20.32–$40.22

Off 52-week high

34.6%

RSI (14)

61

Volume vs avg

1.49×

Score today

4.2/10